Mechanism of Novel FDA Approved Nonhormone Treatment Option for Vasomotor Symptoms Explained

Dr. Susan Reed discusses the first neurokinin 3 (NK3) receptor antagonist approved by FDA to treat moderate to severe hot flashes that works by binding to and blocking the activities of the NK3 receptor, the brain’s thermoregulator. (www.menopause.org)